Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic AsfiledCriticalBavarian Nordic As
Priority claimed from PCT/EP2003/012610external-prioritypatent/WO2004048582A2/en
Publication of BR0316553ApublicationCriticalpatent/BR0316553A/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Micro-Organisms Or Cultivation Processes Thereof
(AREA)
Abstract
"POXVìRUS RECOMBINANTE QUE COMPREENDE PELO MENOS DOIS PROMOTORES ATI DE VARìOLA BOVINA". A invenção refere-se a poxvírus recombinantes que compreendem no genoma viral pelo menos dois cassetes de expressão, cada um compreendendo o promotor ATI de varíola bovina, ou um derivado do mesmo e uma seq³ência codificadora, em que a expressão da seq³ência codificadora é regulada pelo dito promotor. / vírus pode ser útil como uma vacina ou como parte de uma composição farmacêutica."RECOMBINANT POXVIRUS UNDERSTANDING AT LEAST TWO ATI VAROLA BOVINA PROMOTERS". The invention relates to recombinant poxviruses comprising in the viral genome at least two expression cassettes, each comprising the bovine pox ATI promoter, or a derivative thereof and a coding sequence, wherein the expression of the coding sequence is regulated by said prosecutor. Virus may be useful as a vaccine or as part of a pharmaceutical composition.
BR0316553-1A2002-11-252003-11-12
Recombinant poxvirus comprising at least two bovine smallpox ati promoters
BR0316553A
(en)
RECOMBINANT MODIFIED VACCINIA ANKARA VIRAL VECTOR, RECOMBINANT MODIFIED VACCINIA ANKARA, AND, METHOD FOR REDUCING OR PREVENTING A SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 INFECTION